Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Inozyme Pharma is raising $67,399,993.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Axel Bolte played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inozyme Pharma

At Inozyme Pharma we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.

To learn more about Inozyme Pharma, visit http://www.inozyme.com/

Contact:
Axel Bolte, Chief Executive Officer
857-330-4340
axel.bolte@inozyme.com
https://www.linkedin.com/in/axel-bolte-7b542515/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved